Phone
Email
ClinicalTrials.gov URL
Acknowledgement
48 hours
Oncoceutics, Inc.
EA Therapies for Single Patient
ONC201 - H3 K27M mutant gliomas
EA Policies for Single Patient
Oncoceutics will consider single - patient expanded access for patients who meet the criteria for the company's existing expanded access program, as outlined on clinicaltrials.gov